Cephalon's Double Trouble: DoJ Probes Treanda Marketing, Clinical Trial Data
This article was originally published in The Pink Sheet Daily
The inquiry comes three years after the company settled a government investigation of off-label marketing of three other drugs.
You may also be interested in...
The giant Israeli generics firm extols Cephalon's R&D but the deal's real value may be more nuanced: a combination of cost synergies, late-stage pipeline assets, and expansion of Teva's mix of branded products in anticipation of upcoming challenges in both the branded and generics businesses.